Jason A Keyes

CIK 1678152 · Chief Financial Officer · last filed 2026-05-22

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$355.8K

Companies

4

Total Filings

42

Lifetime Open-Market Net

-$384.0K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACTU Director $2.02 $0 3 2026-05-22
EQ Chief Financial Officer 126,633 $2.81 $355.8K -$384.0K 30 2025-02-19
Carisma Therapeutics Inc. (SESN) Delisted Director 40,000 $12.58 $503.0K $0 4 2022-06-24
Orexigen Therapeutics, Inc. (OREX) Delisted EVP, Chief Financial Officer 3,031 $0 5 2017-10-17

Recent Filings · Page 2 of 5

42 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2023-02-07 EQ Grant (A) $0 EDGAR
2023-01-04 EQ Grant (A) +4,444 $5.3K EDGAR
2022-08-30 EQ Sell (S) −7,000 -$19.8K EDGAR
2022-06-24 Carisma Therapeutics Inc. (SESN) Delisted Grant (A) +40,000 $0 EDGAR
2022-06-06 EQ Sell (S) −5,000 -$12.6K EDGAR
2022-04-05 EQ Sell (S) −8,000 -$25.4K EDGAR
2021-12-13 EQ Grant (A) +5,585 $13.1K EDGAR
2021-12-03 EQ Sell (S) −5,000 -$25.4K EDGAR
2021-09-29 EQ Sell (S) −8,000 -$53.9K EDGAR
2021-07-28 EQ Sell (S) −5,000 -$28.6K EDGAR
Showing 1120 of 42
Page 2 of 5
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.